drugset / Trial / NCT07582874

An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia

NCT07582874

Expanded access Available Amylyx Pharmaceuticals Inc.

Summary

The Expanded Access Program will provide access to avexitide for people with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) who meet the eligibility criteria for this program. The safety of avexitide and patient treatment experience will be monitored during this program.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Avexitide Peptide 90 mg Subcutaneous